SHARE NOW
Dr Katie Roberts presents 5 things to consider when sourcing plasmids for a novel gene therapy.
Plasmids are small DNA constructs which act as the building blocks of gene therapies. When transiently or stably transfected into HEK293 cells, these cells act as tiny factories to produce the viral vector needed to deliver therapeutic genes to patient cells.
Enjoying this article? Download the full eBook, here >>
Plasmid quality has a real impact on safety and efficacy of a novel gene therapy and should therefore be considered carefully. In addition to the quality of the plasmids themselves, plasmids should be chosen based on whether they can be easily sourced, are free from legal constraints, and whether they will be compatible with robust manufacturing platforms.
This article will present 5 things to consider when sourcing plasmids for a novel gene therapy.
THIS ARTICLE CONTINUES IN THE FULL EBOOK. DOWNLOAD IT HERE >>
This article has been produced in partnership with WuXi Advanced Therapies. 
More like this
Eureka Therapeutics Awarded $10.6M CIRM Grant for T-Cell Therapy in Pediatric Liver Cancer
Cell and Gene Therapy Catapult Open New Edinburgh, UK, Facilities
BioCentriq® Unveils LEAP™ Advanced Therapy Platform, Enabling Rapid Patient Access for Early-Stage Biotech Companies
Discover more like this
